Sign In
Buy BCC
$76.38
+1.00 (+1.33%)
At Close: Jul 31, 2026
Boise Cascade (BCC) Lags Q1 Earnings Estimates
07:15pm, Monday, 05'th May 2025
Boise Cascade (BCC) came out with quarterly earnings of $1.06 per share, missing the Zacks Consensus Estimate of $1.36 per share. This compares to earnings of $2.61 per share a year ago.
Boise Cascade Reports Lower Sales, Profit as Home Construction Slows
05:10pm, Monday, 05'th May 2025
The maker of wood products said the 2025 market demands are difficult to predict, with most forecasts for housing starts ranging from flat to mid-single-digit declines, year-over-year.
Boise Cascade Company Reports First Quarter 2025 Results
04:15pm, Monday, 05'th May 2025
BOISE, Idaho--(BUSINESS WIRE)--Boise Cascade Company ("Boise Cascade," the "Company," "we," or "our") (NYSE: BCC) today reported net income of $40.3 million, or $1.06 per share, on sales of $1.5 billi
Boise Cascade Company Announces Quarterly Dividend of $0.21 Per Share
04:14pm, Thursday, 01'st May 2025
BOISE, Idaho--(BUSINESS WIRE)--Boise Cascade Company's (Boise Cascade or the Company) (NYSE: BCC) Board of Directors declared a quarterly dividend of $0.21 per share to holders of its common stock. Th
Analysts Estimate Boise Cascade (BCC) to Report a Decline in Earnings: What to Look Out for
11:06am, Monday, 28'th Apr 2025
Boise Cascade (BCC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Boise Cascade: Priced For A Recession, But Built To Survive It
04:49am, Sunday, 27'th Apr 2025
Boise Cascade, a leading wood products' manufacturer, is rated a Buy due to its strong balance sheet and long-term housing market tailwinds, despite short-term cyclical challenges. The company benefit
Boise Cascade Company First Quarter 2025 Earnings Webcast and Conference Call
04:15pm, Tuesday, 22'nd Apr 2025
BOISE, Idaho--(BUSINESS WIRE)--Boise Cascade Company (NYSE: BCC) will host a webcast and conference call to discuss 2025 first quarter earnings on Tuesday, May 6, 2025, at 9:30 a.m. Eastern. To join t
Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC)
07:30am, Monday, 21'st Apr 2025
The Institutional Review Board Has Approved the Increase in Number of Patients from Sixty (60) to Ninety (90). The Company to Expand the Study into Additional Trial Sites in Europe Philadelphia, Penns
New Strong Sell Stocks for April 16th
06:45am, Wednesday, 16'th Apr 2025
BCC, AFLYY and HUN have been added to the Zacks Rank #5 (Strong Sell) List on April 16, 2025.
Chaos? Bring It On: My Dividend Playbook For This Wild Market
07:30am, Monday, 17'th Mar 2025
Volatility is back, and while it's normal, fear dominates. Investors are uneasy despite no official correction, as past gains spoiled expectations. Economic uncertainty, rising debt, and inflation ris
Buying A Dollar For 60 Cents: 2 Dividend Stocks With Potential Upside
07:30am, Friday, 07'th Mar 2025
The market's volatility, driven by geopolitical tensions and tariffs, has created a challenging environment. The sentiment is bearish, but I see opportunities in undervalued, high-quality companies wi
Medicus Pharma reports over 60% complete clearance in Phase 2 BCC trial interim results
09:56am, Thursday, 06'th Mar 2025
Medicus Pharma (NASDAQ:MDCX) has revealed interim results from its Phase 2 clinical trial for a non-invasive treatment targeting basal cell carcinoma (BCC) showing promising efficacy and safety outcom
The Interim Analysis Showed Complete Clinical Clearance of More Than Sixty (60%) Percent The Interim Analysis Showed Complete Clinical Clearance of More Than Sixty (60%) Percent
The Clinical Study is Expected to Randomize 36 Participants in Cleveland Clinic Abu Dhabi (CCAD) and Three Other Clinical Sites in UAE The Clinical Study is Expected to Randomize 36 Participants in Cl
Boise Cascade Q4 Earnings Miss, Sales Top, Adjusted EBITDA Down Y/Y
12:50pm, Monday, 24'th Feb 2025
BCC's fourth-quarter 2024 results reflect unfavorable sales price trends. Dive in to learn more about the quarterly performance.
